Nemus Bioscience Financing
Nemus Bioscience, Inc., Corporation just filed form D for $500,000 equity financing. This is a new filing. Nemus Bioscience was able to finance itself with $500,000. That is 100.00% of the fundraising offer. The total financing amount was $500,000. The fundraising form was filed on 2016-11-03. The reason for the financing was: Additional Sales Compensation-warrants to purchase 125,000 shares of common stock..
Nemus Bioscience is based in California. The company’s business is Pharmaceuticals. The SEC form was signed by Elizabeth M Berecz Chief Financial Officer. The company was incorporated in 2011. The filler’s address is: 650 Town Center Drive, Suite 1770, Costa Mesa, Ca, California, 92626. Cosmas N. Lykos is the related person in the form and it has address: 650 Town Center Drive, Suite 1770, Costa Mesa, Ca, California, 92626. Link to Nemus Bioscience Filing: 000114036116084761.
Analysis of Nemus Bioscience Offering
On average, firms in the Pharmaceuticals sector, sell 60.90% of the total offering size. Nemus Bioscience sold 100.00% of the offering. Could this mean that the trust in Nemus Bioscience is high? The average financing size for companies in the Pharmaceuticals industry is $556,000. The offering was 10.07% smaller than the average of $556,000. Of course this should not be seen as negative. Companies get financed for a variety of needs and reasons. The minimum investment for this offering is set at $0. If you know more about the reasons for the financing, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Nemus Bioscience Also
The Form D signed by Elizabeth M Berecz might help Nemus Bioscience, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.